Related Experiment Video
Updated: May 9, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Updates in the management of high-grade glioma
1The National Hospital for Neurology and Neurosurgery, Queen Square, Mailbox 99, London, WC1N 3BG, UK, davidbradley@physicians.ie.
Insights
High-grade glioma (HGG) management has advanced, improving patient survival and quality of life. This review covers key HGG treatment developments from the past five years.
Area of Science:
- Neuro-oncology
- Clinical Medicine
Background:
- High-grade glioma (HGG) management has seen significant evolution.
- Multidisciplinary team (MDT) approaches are crucial for evidence-based HGG care.
- Patient outcomes for HGG, though challenging, show incremental improvements.
Purpose of the Study:
- To review recent advancements in high-grade glioma management.
- To highlight key developments in HGG treatment over the last five years.
Main Methods:
- Literature review of recent studies and clinical guidelines.
- Synthesis of evidence-based treatment strategies for HGG.
Main Results:
- Significant progress in HGG treatment protocols.
- Improved survival rates and quality of life for HGG patients.
- Emerging therapeutic strategies impacting HGG care.
Conclusions:
- Recent advancements have positively impacted HGG patient outcomes.
- Continued evolution in HGG management offers hope for better prognoses.
- Multidisciplinary care remains central to optimizing HGG treatment.
Abstract:
The management of high-grade glioma (HGG) has evolved significantly over the last decade. Patients are managed in a multidisciplinary team setting in order to ensure their care is guided by the most current evidenced based treatments. The outcome in patients with HGG, while still poor, has improved in terms of both survival and quality of life during illness. This review discusses a number of developments seen in the management of HGG over the last 5 years.
